Tag Archives: biopharmaceuticals

Biopharmaceuticals: Approvals Rate Best in Five Years

Overall, last year can be considered quite a successful one in terms of new product approvals. Nineteen products containing new biopharmaceutical molecular entities were approved in the United States and/or the European Union. These approval numbers are above average compared to the previous five years, which recorded a mean approval rate of 13 products. The […]
Posted in Biotech, Europe, Global, Guest Blog, Regulatory | Also tagged , | Leave a comment

Baxter Splits Biopharm and Medical Products into Two Businesses

Baxter International plans to create two separate, independent global healthcare companies, with one focused on biopharmaceuticals and the other on medical products.
Posted in Biotech, Strategy | Also tagged , | Leave a comment

Biopharma's High Performers 2014

Accenture has launched the latest version of its annual study of the biopharmaceutical industry. The High Performance Business (HPB) report analyses  the long-term performance of the 16 largest pharma companies globally, highlighting industry trends, pharmaceutical business performance analysis, and potential implications for the industry.
Posted in Biotech, Global, Strategy | Also tagged , , , , | Leave a comment

Shrinking Economy Hits California Biosector

By Amy Ritter, Pharmaeutical Technology. A report released on Feb. 8, 2012 from the California Healthcare Institute, BayBio and PwC shows that the shrinking economy, changes in investment strategies, and pressures on the pharmaceutical market have put the brakes on one of the US’s most robust biotechnology centers. California had enjoyed steady growth in its […]
Posted in Biotech, Guest Blog | Also tagged , , , | Leave a comment

California Biotech — Good Governance Tops Wish List

New industry survey data documents a fraying investment base marked by a distant and unresponsive FDA as well as an unprepared work force complacent about hungry foreign competition. California’s biotech industry has taken its annual pulse of business conditions — and while the prognosis is not for putting the state on the policy equivalent of […]
Posted in Biotech, FDA, healthcare, R&D, Strategy | Also tagged , , , , | Leave a comment
  • Categories

  • Meta